Previous 10 | Next 10 |
SAN DIEGO , April 1, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, announced today that its Phase 1b /2 clinical tri...
TrovaGene (NASDAQ: TROV ): Q4 GAAP EPS of -$0.51 beats by $0.14 . More news on: TrovaGene, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal ...
Nano cap Trovagene (NASDAQ: TROV ) slumps 10% premarket on increased volume on the heels of preliminary data from a Phase 2 clinical trial evaluating lead drug onvansertib, combined with J&J's Zytiga (abiraterone acetate) and prednisone, in patients with abiraterone-resis...
XBiotech (NASDAQ: XBIT ) -26% on preliminary results of tender offer . More news on: XBiotech Inc., Akorn, Inc., Catalyst Biosciences, Inc., Stocks on the move, , Read more ...
SAN DIEGO , Feb. 13, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced positive data from its ongoing Phase 2...
Penny Stocks To Have On The Radar Right Now One of the biggest things to pay attention to when it comes to penny stocks is timing. I’m not saying that you need to perfectly time a trade. This is more in reference to understanding that some times may be better than others to take a clo...
SAN DIEGO , Feb. 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced that a poster featuring efficacy d...
Tonix Pharmaceuticals (TNXP) reported favorable results for the tests on its lead drug candidate TNX 102 SL. The pharma company had conducted fed-fasting and dose proportionality tests of the drug candidate in healthy volunteers. The data will be used to support a New Drug Application for trea...
January 30, 2020 FN Media Group Presents USA News Group Market Commentary Los Angeles, CA – January 30, 2020 – USA News Group – The rapidly spreading Wuhan coronavirus or 2019-nCoV has set off all kinds of alerts in agencies across the globe. To help relieve...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...